Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01603264 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
105
Enrollment target

NCT01603264: Completed Phase 1 study, sponsored by Pfizer.

NCT01603264 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01603264, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
105 participants
Enrollment target

Study Summary

In this study, healthy male volunteers will receive a single intravenous administration of either PF-05280014 or trastuzumab (United States) or trastuzumab (European Union). During the course of the study, the pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms of PF-05280014 and the US-licensed and EU-approved trastuzumab products. Safety, tolerability, and immunologic response also will be evaluated throughout.

Interventions

  • BIOLOGICAL PF-05280014
  • BIOLOGICAL Herceptin

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2012-05
Est. Completion 2012-12
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01603264 record still lists

NCT01603264 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).

The record links to 0 conditions, and to 2 interventions - of which PF-05280014 is the first listed.

NCT01603264 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01603264 about?

NCT01603264 is a clinical study titled "A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)". In this study, healthy male volunteers will receive a single intravenous administration of either PF-05280014 or trastuzumab (United States) or trastuzumab (European Union). During the course of the study, the pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comp...

What is the current status of trial NCT01603264?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2012-05. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01603264?

The interventions under investigation include: PF-05280014 (BIOLOGICAL), Herceptin (BIOLOGICAL).

Who is sponsoring clinical trial NCT01603264?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01603264's enrollment target sits among peer trials

105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01603264, the US trial registry maintained by the National Library of Medicine. NCT01603264 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.